Analysts Set Agenus Inc. (NASDAQ:AGEN) Price Target at $10.00

Shares of Agenus Inc. (NASDAQ:AGEN) have earned an average recommendation of “Hold” from the six brokerages that are currently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $10.00.

Several equities research analysts have commented on the stock. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. B. Riley decreased their price target on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Finally, HC Wainwright dropped their price target on Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday, November 12th.

Agenus Trading Up 6.3 %

NASDAQ AGEN opened at $3.55 on Thursday. The business has a fifty day simple moving average of $4.36 and a 200 day simple moving average of $8.25. Agenus has a 12 month low of $2.50 and a 12 month high of $19.69. The firm has a market capitalization of $83.28 million, a P/E ratio of -0.32 and a beta of 1.39.

Institutional Investors Weigh In On Agenus

A number of hedge funds have recently modified their holdings of AGEN. BNP Paribas Financial Markets raised its stake in shares of Agenus by 81.3% in the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 84,477 shares during the period. Vanguard Group Inc. raised its stake in Agenus by 13.7% in the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after acquiring an additional 4,134,232 shares during the period. Acadian Asset Management LLC lifted its holdings in Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after purchasing an additional 720,629 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Agenus by 52.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 123,058 shares during the period. Finally, Federated Hermes Inc. purchased a new position in shares of Agenus in the second quarter worth about $1,921,000. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.